Takashi Seishi Selected Research

Oral Administration

11/2003

Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takashi Seishi Research Topics

Disease

1	Spinal Cord Injuries (Spinal Cord Injury) 01/2014
1	Overactive Urinary Bladder (Overactive Bladder) 01/2014
1	Neointima 11/2003

Drug/Important Bio-Agent (IBA)

1	draflazineIBA 01/2014
1	KW 7158IBA 01/2014
1	NucleosidesIBA 01/2014
1	Dipyridamole (Persantine)FDA LinkGeneric 01/2014
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 11/2003

Therapy/Procedure

1	Oral Administration 11/2003